JP3860605B2 - 補体活性化をブロックするキメラタンパク質 - Google Patents

補体活性化をブロックするキメラタンパク質 Download PDF

Info

Publication number
JP3860605B2
JP3860605B2 JP50995795A JP50995795A JP3860605B2 JP 3860605 B2 JP3860605 B2 JP 3860605B2 JP 50995795 A JP50995795 A JP 50995795A JP 50995795 A JP50995795 A JP 50995795A JP 3860605 B2 JP3860605 B2 JP 3860605B2
Authority
JP
Japan
Prior art keywords
chimeric protein
protein
mcp
soluble
convertase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50995795A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09502985A (ja
Inventor
コ，ジョーン−ロン
ジェイ． ヒギンズ，ポール
イェイ，シー．グレイス
Original Assignee
ミレニアム ファーマスーティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミレニアム ファーマスーティカルズ， インコーポレイテッド filed Critical ミレニアム ファーマスーティカルズ， インコーポレイテッド
Publication of JPH09502985A publication Critical patent/JPH09502985A/ja
Application granted granted Critical
Publication of JP3860605B2 publication Critical patent/JP3860605B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP50995795A 1993-09-24 1994-09-23 補体活性化をブロックするキメラタンパク質 Expired - Fee Related JP3860605B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/126,596 1993-09-24
US08/310,416 1994-09-22
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation
PCT/US1994/010786 WO1995008570A1 (en) 1993-09-24 1994-09-23 Chimeric proteins which block complement activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004282827A Division JP2005041882A (ja) 1993-09-24 2004-09-28 補体活性化をブロックするキメラタンパク質

Publications (2)

Publication Number Publication Date
JPH09502985A JPH09502985A (ja) 1997-03-25
JP3860605B2 true JP3860605B2 (ja) 2006-12-20

Family

ID=26824842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50995795A Expired - Fee Related JP3860605B2 (ja) 1993-09-24 1994-09-23 補体活性化をブロックするキメラタンパク質
JP2004282827A Withdrawn JP2005041882A (ja) 1993-09-24 2004-09-28 補体活性化をブロックするキメラタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004282827A Withdrawn JP2005041882A (ja) 1993-09-24 2004-09-28 補体活性化をブロックするキメラタンパク質

Country Status (9)

Country Link
US (2) US5679546A (enExample)
EP (1) EP0723555B1 (enExample)
JP (2) JP3860605B2 (enExample)
CN (1) CN1057097C (enExample)
AT (1) ATE380875T1 (enExample)
AU (1) AU697167B2 (enExample)
CA (1) CA2172610A1 (enExample)
DE (1) DE69435049D1 (enExample)
WO (1) WO1995008570A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
WO2001032901A1 (en) * 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
PT1569685E (pt) * 2002-11-15 2012-11-02 Univ Colorado Regents Recetor do complemento 2 direcionado a moduladores do complemento
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
AU2005231395B2 (en) * 2004-03-31 2011-06-16 The Fernstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
CL2007003161A1 (es) * 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
CN103038252A (zh) 2010-05-14 2013-04-10 科罗拉多大学董事会,法人团体 改良的补体受体2(cr2)靶向群
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
AU2013243570B2 (en) 2012-04-03 2017-12-14 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
SG10202104175YA (en) 2014-02-27 2021-06-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018503368A (ja) 2014-12-18 2018-02-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
IL296929B2 (en) * 2015-09-24 2025-07-01 Univ Pennsylvania Composition and method for treating complement-mediated disease
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
DK3474883T3 (da) 2016-06-28 2022-08-29 Univ Ulm Komplementinhibitorer og anvendelser deraf
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3956347A4 (en) * 2019-04-13 2023-09-20 National Centre For Cell Science DAF-MCP CHIMERIC PROTEINS, THEIR MANUFACTURING METHOD AND USE OF THE CHIMERIC PROTEIN TO TREAT PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
DK0489116T3 (da) * 1989-08-22 1994-05-02 Immunex Corp Fusionsproteiner omfattende GM-CSF og IL-3
CA2049964A1 (en) * 1990-01-26 1991-07-27 Mark P. Pasek C4 binding protein fusion proteins
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
JPH09502985A (ja) 1997-03-25
CN1138863A (zh) 1996-12-25
WO1995008570A1 (en) 1995-03-30
US5679546A (en) 1997-10-21
AU8071994A (en) 1995-04-10
EP0723555A1 (en) 1996-07-31
EP0723555B1 (en) 2007-12-12
DE69435049D1 (de) 2008-01-24
AU697167B2 (en) 1998-10-01
EP0723555A4 (en) 1999-04-28
ATE380875T1 (de) 2007-12-15
CA2172610A1 (en) 1995-03-30
JP2005041882A (ja) 2005-02-17
US5851528A (en) 1998-12-22
CN1057097C (zh) 2000-10-04

Similar Documents

Publication Publication Date Title
JP3860605B2 (ja) 補体活性化をブロックするキメラタンパク質
WO1995008570A9 (en) Chimeric proteins which block complement activation
US6316604B1 (en) Human C3b/C4b receptor (CR1)
JP3097753B2 (ja) ヒトＣ３ｂ／Ｃ４ｂレセプター（ＣＲ１）
JP3484189B2 (ja) ヒトＣ３ｂ／Ｃ４ｂレセプター （ＣＲ１）
JP4145356B2 (ja) Ｐ―セレクチンリガンド蛋白
JP3542127B2 (ja) ヒトインターフェロン―β２／インターロイキン―６受容体
FI100994B (fi) Menetelmä valmistaa ICAM-2 ja yhdistelmä-DNA-molekyyli
EP0666914B1 (en) Novel p-selectin ligand protein
CA2020729A1 (en) Bone morphogenetic protein
US20110274711A1 (en) Hla-g polypeptides and pharmaceutical uses thereof
JPH05501398A (ja) 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
EP0636177A1 (en) ISOLATION, CHARACTERIZATION, AND USE OF THE HUMAN $g(b) SUBUNIT OF THE HIGH AFFINITY RECEPTOR FOR IMMUNOGLOBULIN E
US8932601B2 (en) Hybrid and chimeric polypeptides that regulate activation of complement
US7176180B2 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO1995004756A1 (en) Complement inhibitor proteins of non-human primates
PT93394B (pt) Processo para a preparacao de celulas de hibridonas produzindo anticorpos ligaveis a moleculas de adesao intercelular
MXPA97004173A (en) Designated citoquina lce

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060922

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100929

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110929

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110929

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120929

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130929

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees